- Home
- OPP vs NKTR Comparison
OPP vs NKTR Comparison
Compare OPP & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPP
- NKTR
- Stock Information
- Founded
- OPP 2010
- NKTR 1990
- Country
- OPP United States
- NKTR United States
- Employees
- OPP N/A
- NKTR N/A
- Industry
- OPP Finance/Investors Services
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- OPP Finance
- NKTR Health Care
- Exchange
- OPP Nasdaq
- NKTR Nasdaq
- Market Cap
- OPP 206.5M
- NKTR 238.7M
- IPO Year
- OPP N/A
- NKTR 1994
- Fundamental
- Price
- OPP $8.89
- NKTR $1.45
- Analyst Decision
- OPP
- NKTR Buy
- Analyst Count
- OPP 0
- NKTR 4
- Target Price
- OPP N/A
- NKTR $2.50
- AVG Volume (30 Days)
- OPP 108.0K
- NKTR 1.3M
- Earning Date
- OPP 01-01-0001
- NKTR 11-05-2024
- Dividend Yield
- OPP 14.41%
- NKTR N/A
- EPS Growth
- OPP N/A
- NKTR N/A
- EPS
- OPP N/A
- NKTR N/A
- Revenue
- OPP N/A
- NKTR $93,157,000.00
- Revenue This Year
- OPP N/A
- NKTR N/A
- Revenue Next Year
- OPP N/A
- NKTR N/A
- P/E Ratio
- OPP N/A
- NKTR N/A
- Revenue Growth
- OPP N/A
- NKTR 6.17
- 52 Week Low
- OPP $7.26
- NKTR $0.41
- 52 Week High
- OPP $8.83
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- OPP 36.83
- NKTR 63.84
- Support Level
- OPP $8.98
- NKTR $1.27
- Resistance Level
- OPP $9.11
- NKTR $1.39
- Average True Range (ATR)
- OPP 0.09
- NKTR 0.09
- MACD
- OPP -0.02
- NKTR 0.01
- Stochastic Oscillator
- OPP 2.36
- NKTR 88.89
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.